Skip to content

Sutro Biopharma STRO Free cash flow margin

Free cash flow margin at other companies

Pfizer logo
PfizerPFE
18%+8.8pp
Gilead Sciences logo
Gilead SciencesGILD
34.4%+0.1pp
Regenxbio logo
RegenxbioRGNX
-269.2%-364pp
Xencor logo
XencorXNCR
-194%+166pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
1.9%+1.0pp
Schrodinger logo
SchrodingerSDGR
9.6%+5.1pp

Other financials

Income statement

See full
Revenue$14.5M-16.5%
Operating income-$29.7M+56.7%
Net income-$38.5M+49.3%
EPS (diluted)-$2.94+67.6%

Balance sheet

See full
Cash & equivalents$73.7M-30.6%
Total debt$13.6M-36.3%
Total equity-$66.9M-159%
Total assets$242.0M-24.7%

Cash flow

See full
Operating cash flow-$42.3M+37.7%
CapEx--100%
Free cash flow-$42.3M+37.8%

Valuation

See full
Market cap$489.66M+624%
Enterprise value$429.61M-2,600%
P/S4.9×+3.9×

Profitability

See full
Operating margin-120%-48.6pp
Net margin-154.2%-56.7pp

Returns & leverage

See full
Return on equity-234.2%
Debt / equity0.5×+0.3×
Current ratio3.1×+1.0×

Where this comes from

Calculated from Sutro Biopharma’s reported figures.

Based on trailing twelve months.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sutro Biopharma's free cash flow margin?
Sutro Biopharma (STRO) reported free cash flow margin of -152.2% in Q1 2026.
How has Sutro Biopharma's free cash flow margin changed year-over-year?
Sutro Biopharma's free cash flow margin increased by 50.6% year-over-year, from -308.1% to -152.2%.
What is the long-term trend for Sutro Biopharma's free cash flow margin?
Over 3 years (2020 to 2025), Sutro Biopharma's free cash flow margin has grown at a 2.6% compound annual growth rate (CAGR), from -160% to -172.9%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.